Though perhaps true before, now that Vitiligo (which is further along in development) has the green light this is basically a non issue assuming Phase 3 confirms previous trials as expected.
Ann: SCENESSE provides photoprotection in variegate porphyria, page-9
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.80 |
Change
0.210(1.44%) |
Mkt cap ! $739.1M | |||
| Open | High | Low | Value | Volume |
| $14.76 | $14.96 | $14.46 | $1.093M | 74.25K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38 | $15.68 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.32 | 870 | 1 |
View Market Depth
| Last trade - 15.59pm 31/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |